Hemostats Industry Development & Worldwide Its Wide Range of Applications to USD 4.5 Billion by 2024

Global Hemostats Market, By Product Type (Thrombin Based, Combination, Oxidized Regenerated Cellulose Based, Gelatin Based, Collagen Based Hemostat), By Indication (Wound Closure, Surgery), By End-User (Hospitals, Clinics, Ambulatory Centers, Community Healthcare, Others), By Geography (North America, South America, Europe, Asia-Pacific, Middle East and Africa) and Forecast to 2024.

Get Free Sample Report @ http://databridgemarketresearch.com/request-a-sample/?dbmr=global-hemostats-market

Global Hemostats Market is expected to reach USD 4.5 billion by 2024 from USD 2.7 billion in 2016, at a CAGR of 6.6% in the forecast period 2017 to 2024. The new market report contains data for historic years 2015, the base year of calculation is 2016 and the forecast period is 2017 to 2024.

Key Points:

Ethicon US LLC (U.S.) is dominating the hemostats market followed by Pfizer and C.R. Bard Inc., along with others such as Baxter, Vascular Solutions, Inc., B.Braun Melsungen, 3-D Matrix, Ltd., Resorba Medical GmbH (an Advanced Medical Solutions Group plc Company), Anika Therapeutics, Inc., Arch Therapeutics Inc., Biom’Up SAS, CryoLife, Inc., Gamma Therapeutics, Inc., Hemostasis, LLC, MedTrade Products Limited, Integra LifeSciences Corporation, Medline Industries, Inc., HEMOTEC MEDICAL GMBH, Stryker, CSL Behring, Mallinckrodt, and Equimedical, B.V. among other companies.

Combination agents market is growing with the highest CAGR.

Thrombin based hemostats is driving the market with the highest market share.

Surgery is dominating the application segment in the hemostats market.

Inquiry before buying @ http://databridgemarketresearch.com/inquire-before-buying/?dbmr=global-hemostats-market

Key Drivers:

Some of the major factors driving the market for hemostats market are increasing number of surgeries, technological advancement, increasing healthcare expenditure and infrastructure. These factors are increasing the demand for different heomostatic agents.

Reluctance of surgeons towards new products may hinder the growth of this market.

The weak reimbursement scenario will hamper the growth of the market for new and innovative therapies or hemostats products, causing companies to withdraw from the market thus increasing the hospital costs putting all burdens onto the patient for treatment.

Market Segmentation:

The Global Hemostats Market is segmented on the basis of type, application, distribution channel, and end user. The global hemostats market is segmented into 5 major types, namely thrombin based hemostats, combination agents, oxidized regenerated cellulose based haemostats, gelatin based haemostats and collagen based haemostats. In 2017, the thrombin based hemostats segment is expected to dominate the market with a share of ~38.0% and collagen agents is expected to grow with the highest CAGR during the forecast period from 2017 to 2024.

On the basis of application, the market is segmented into surgery and wound closure.

On the basis of end users, the market is classified into hospitals, community healthcare, ambulatory centres and clinics. In 2017, the hospital segment is expected to dominate the market and is expected to continue this trend till 2024.

View Full Report @ http://databridgemarketresearch.com/reports/global-hemostats-market/

TABLE OF CONTENTS :

1. INTRODUCTION

1.1. OBJECTIVES OF THE STUDY
1.2. MARKET DEFINITION
1.3. OVERVIEW OF GLOBAL HEMOSTATS MARKET
1.4. CURRENCY AND PRICING
1.5. LIMITATION
1.6. MARKETS COVERED

2. MARKET SEGMENTATION

2.1. MARKETS COVERED
2.2. GEOGRAPHIC SCOPE
2.3. YEARS CONSIDERED FOR THE STUDY
2.4. CURRENCY AND PRICING
2.5. RESEARCH METHODOLOGY
2.6. PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.7. SECONDARY SOURCE
2.8. ASSUMPTIONS

3. MARKET OVERVIEW

3.1. DRIVERS

3.1.1. CHRONIC CONDITIONS AND AGING POPULATION LEADING TO INCREASE IN NUMBER OF SURGICAL PROCEDURES
3.1.2. TECHNOLOGICAL ADVANCEMENTS
3.1.3. INCREASING NUMBER OF MINIMALLY INVASIVE SURGERIES
3.1.4. IMPROVING HEALTHCARE INFRASTRUCTURE AND INCREASING HEALTHCARE SPENDING

3.2. RESTRAINTS

3.2.1. RELUCTANCE OF SURGEONS TOWARDS NEW PRODUCTS
3.2.2. WEAK REIMBURSEMENT

3.3. OPPORTUNITIES

3.3.1. UNMET MEDICAL NEEDS
3.3.2. EMERGING MARKET

3.4. CHALLENGES

3.4.1. DEVELOPMENT OF SUBSTITUTE PRODUCTS
3.4.2. LIMITATIONS OF HEMOSTATIC AGENTS IN ACHIEVING HEMOSTASIS

4. PREMIUM INSIGHTS

5. REGULATORY

5.1. OVERVIEW
5.2. REGULATORY PROCEDURE

6. REIMBURSEMENT

6.1. OVERVIEW
6.2. REIMBURSEMENT SCENARIO

7. EXECUTIVE SUMMARY

8. GLOBAL HEMOSTATS MARKET, BY TYPE

8.1. OVERVIEW
8.2. THROMBIN BASED HEMOSTATS
8.3. COMBINATION AGENT HEMOSTATS
8.4. OXIDIZED REGENERATED CELLULOSE BASED HEMOSTATS
8.5. GELATIN BASED HEMOSTATS
8.6. COLLAGEN BASED HEMOSTATS

9. GLOBAL HEMOSTATS MARKET,BY APPLICATION

9.1. OVERVIEW
9.2. GLOBAL HEMOSTATS MARKET, BY APPLICATION
9.3. WOUND CLOSURE
9.4. SURGICAL HEMOSTATS

10. GLOBAL HEMOSTATS MARKET, BY DISTRIBUTION CHANNEL

10.1. OVERVIEW
10.1.1. DIRECT TENDERS
10.1.2. RETAIL

11. GLOBAL HEMOSTATS MARKET, BY END USER

11.1. OVERVIEW
11.2. HOSPITALS
11.3. AMBULATORY CENTERS
11.4. COMMUNITY HEALTHCARE
11.5. CLINICS

12. GLOBAL HEMOSTATS MARKET, BY GEOGRAPHY

12.1. OVERVIEW

12.2. NORTH AMERICA

12.2.1. U.S.
12.2.2. CANADA
12.2.3. MEXICO

12.3. EUROPE

12.3.1. GERMANY
12.3.2. FRANCE
12.3.3. U.K.
12.3.4. ITALY
12.3.5. SPAIN
12.3.6. RUSSIA
12.3.7. TURKEY
12.3.8. BELGIUM
12.3.9. NETHERLANDS
12.3.10. SWITZERLAND
12.3.11. REST OF EUROPE

12.4. ASIA-PACIFIC (APAC)

12.4.1. JAPAN
12.4.2. CHINA
12.4.3. SOUTH KOREA
12.4.4. INDIA
12.4.5. AUSTRALIA
12.4.6. SINGAPORE
12.4.7. THAILAND
12.4.8. MALAYSIA
12.4.9. INDONESIA
12.4.10. PHILIPPINES
12.4.11. REST OF APAC

12.5. SOUTH AMERICA

12.5.1. BRAZIL
12.5.2. REST OF SOUTH AMERICA

12.6. MEA

12.6.1. SOUTH AFRICA
12.6.2. REST OF MEA

13. GLOBAL HEMOSTATS MARKET, COMPANY LANDSCAPE

13.1. COMPANY SHARE ANALYSIS: GLOBAL
13.2. COMPANY SHARE ANALYSIS: NORTH AMERICA
13.3. COMPANY SHARE ANALYSIS: EUROPE
13.4. COMPANY SHARE ANALYSIS: APAC

14. COMPANY PROFILES

14.1. ETHICON US, LLC (SUBSIDIARY OF JOHNSON & JOHNSON SERVICES, INC)

14.1.1. COMPANY OVERVIEW
14.1.2. REVENUE ANALYSIS
14.1.3. PRODUCT PORTFOLIO
14.1.4. RECENT DEVELOPMENTS

14.2. PFIZER

14.2.1. COMPANY OVERVIEW
14.2.2. REVENUE ANALYSIS
14.2.3. PRODUCT PORTFOLIO
14.2.4. RECENT DEVELOPMENTS

14.3. C.R BARD

14.3.1. COMPANY OVERVIEW
14.3.2. REVENUE ANALYSIS
14.3.3. PRODUCT PORTFOLIO
14.3.4. RECENT DEVELOPMENTS

14.4. BAXTER

14.4.1. COMPANY OVERVIEW
14.4.2. REVENUE ANALYSIS
14.4.3. PRODUCT PORTFOLIO
14.4.4. RECENT DEVELOPMENTS

14.5. VASCULAR SOLUTIONS, INC (ACQUIRED BY TELEFLEX INCORPORATED)

14.5.1. COMPANY OVERVIEW
14.5.2. REVENUE ANALYSIS
14.5.3. PRODUCT PORTFOLIO
14.5.4. RECENT DEVELOPMENTS

14.6. B.BRAUN MELSUNGEN AG

14.6.1. COMPANY OVERVIEW
14.6.2. REVENUE ANALYSIS
14.6.3. PRODUCT PORTFOLIO
14.6.4. RECENT DEVELOPMENTS

14.7. 3-D MATRIX LTD

14.7.1. COMPANY OVERVIEW
14.7.2. REVENUE ANALYSIS
14.7.3. PRODUCT PORTFOLIO
14.7.4. RECENT DEVELOPMENTS

14.8. RESORBA MEDICAL GMBH

14.8.1. COMPANY OVERVIEW
14.8.2. REVENUE ANALYSIS
14.8.3. PRODUCT PORTFOLIO
14.8.4. RECENT DEVELOPMENTS

14.9. ANIKA THERAPEUTICS, INC.

14.9.1. COMPANY OVERVIEW
14.9.2. REVENUE ANALYSIS
14.9.3. PRODUCT PORTFOLIO
14.9.4. RECENT DEVELOPMENTS

14.10. BIOM’UP

14.10.1. COMPANY OVERVIEW
14.10.2. REVENUE ANALYSIS
14.10.3. PRODUCT PORTFOLIO
14.10.4. RECENT DEVELOPMENTS

14.11. CRYOLIFE, INC.

14.11.1. COMPANY OVERVIEW
14.11.2. REVENUE ANALYSIS
14.11.3. PRODUCT PORTFOLIO
14.11.4. RECENT DEVELOPMENTS

14.12. EQUIMEDICAL

14.12.1. COMPANY OVERVIEW
14.12.2. REVENUE ANALYSIS
14.12.3. PRODUCT PORTFOLIO
14.12.4. RECENT DEVELOPMENTS

14.13. HEMOSTASIS, LLC

14.13.1. COMPANY OVERVIEW
14.13.2. REVENUE ANALYSIS
14.13.3. PRODUCT PORTFOLIO
14.13.4. RECENT DEVELOPMENTS

14.14. MEDTRADE PRODUCTS LIMITED

14.14.1. COMPANY OVERVIEW
14.14.2. REVENUE ANALYSIS
14.14.3. PRODUCT PORTFOLIO
14.14.4. RECENT DEVELOPMENTS

14.15. STRYKER

14.15.1. COMPANY OVERVIEW
14.15.2. REVENUE ANALYSIS
14.15.3. PRODUCT PORTFOLIO
14.15.4. RECENT DEVELOPMENTS

14.16. ARCH THERAPEUTICS, INC.

14.16.1. COMPANY OVERVIEW
14.16.2. REVENUE ANALYSIS
14.16.3. PRODUCT PORTFOLIO
14.16.4. RECENT DEVELOPMENTS

14.17. INTEGRA LIFESCIENCES CORPORATION

14.17.1. COMPANY OVERVIEW
14.17.2. REVENUE ANALYSIS
14.17.3. PRODUCT PORTFOLIO
14.17.4. RECENT DEVELOPMENTS

14.18. ALTAYLAR MEDICAL

14.18.1. COMPANY OVERVIEW
14.18.2. REVENUE ANALYSIS
14.18.3. PRODUCT PORTFOLIO
14.18.4. RECENT DEVELOPMENTS

14.19. BIOCER ENTWICKLUNGS-GMBH

14.19.1. COMPANY OVERVIEW
14.19.2. REVENUE ANALYSIS
14.19.3. PRODUCT PORTFOLIO
14.19.4. RECENT DEVELOPMENTS

14.20. SMI (STARCH MEDICAL)

14.20.1. COMPANY OVERVIEW
14.20.2. REVENUE ANALYSIS
14.20.3. PRODUCT PORTFOLIO
14.20.4. RECENT DEVELOPMENTS

Related Report

Global Hernia Repair Devices Market – Industry Trends and Forecast to 2024

Global Hernia Repair Devices Market By Product Type, End User, Geography (North America, Europe, APAC, South America, MEA)–Industry Trends and Forecast to 2024

Report Access: http://databridgemarketresearch.com/reports/global-hernia-repair-devices-market/

About Data Bridge Market Research:
Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact:
Vishal Dixit
Data Bridge Market Research
Tel: +1-888-387-2818
Email: sopan.gedam@databridgemarketresearch.com

This release was published on openPR.